Skip to content

Clinical trials

Tuberculosis, Multidrug-Resistant trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Tuberculosis, Multidrug-Resistant Country / region: China Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20094
20101
20142
20161
20182
20191
20203
20212
20224
20231
20241
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Unknown status8
Recruiting3
Not yet recruiting2
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Huashan Hospital7
Beijing Chest Hospital5
Shanghai Pulmonary Hospital, Shanghai, China3
Janssen Infectious Diseases BVBA2
Otsuka Pharmaceutical Development & Commercialization, Inc.2
Chinese University of Hong Kong1
Karolinska Institutet1
National Institute of Allergy and Infectious Diseases (NIAID)1
Shanghai Jiatan Pharmatech Co., Ltd1
The First Affiliated Hospital with Nanjing Medical University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Tuberculosis, Multidrug-Resistant25
Tuberculosis5
Tuberculosis, Pulmonary5
Extensively Drug-Resistant Tuberculosis2
Latent Tuberculosis1
Tuberculosis, Extrapulmonary1

Trials

Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.